B. Riley Wealth Advisors Inc. Acquires 7,155 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

B. Riley Wealth Advisors Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 25.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 35,674 shares of the biopharmaceutical company’s stock after purchasing an additional 7,155 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $2,448,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Quarry LP bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $43,000. Sunbelt Securities Inc. grew its holdings in Gilead Sciences by 35.1% in the second quarter. Sunbelt Securities Inc. now owns 15,678 shares of the biopharmaceutical company’s stock worth $1,076,000 after purchasing an additional 4,075 shares during the period. Magnolia Capital Advisors LLC bought a new stake in Gilead Sciences in the second quarter valued at $461,000. Creative Planning raised its holdings in shares of Gilead Sciences by 8.4% during the second quarter. Creative Planning now owns 188,594 shares of the biopharmaceutical company’s stock valued at $12,939,000 after purchasing an additional 14,544 shares during the period. Finally, Doheny Asset Management CA bought a new position in shares of Gilead Sciences during the 2nd quarter worth about $2,688,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 0.1 %

NASDAQ:GILD opened at $83.94 on Wednesday. The firm’s 50 day moving average is $78.53 and its 200 day moving average is $71.67. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The stock has a market capitalization of $104.58 billion, a PE ratio of 233.17, a price-to-earnings-growth ratio of 2.91 and a beta of 0.18. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Sell-side analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.67%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 price target on shares of Gilead Sciences in a research note on Wednesday, September 11th. BMO Capital Markets increased their target price on Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Robert W. Baird restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Thursday, June 20th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Finally, Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective for the company in a report on Monday, July 8th. Twelve equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $82.06.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.